University of Heidelberg
BIOQUANT

Breaking News:

03/03/2016 19:02

3 postdoc positions available

Wanted: Postdocs to work on exciting clinically-oriented AAV evolution projects funded by international European consortia and the industry.

Please...


Publications

2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 - 1997

2017

  • L. Amoasii, C. Long, H. Li, A.A. Mireault, J.M. Shelton, E. Sanchez-Ortiz, J.R. McAnally, S. Bhattacharyya, F. Schmidt, D. Grimm, S.D. Hauschka, R. Bassel-Duby, and E. Olson. Single cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl. Med., in press.
  • C. Kunze, K. Börner, E. Kienle, T. Orschmann, E. Rusha, M. Schneider, M. Radivojkov-Blagojevic, M. Drukker, S. Desbordes, D. Grimm, and R. Brack-Werner. Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia, in press.
  • D. Grimm, and H. Büning. Small but increasingly mighty - Latest advances in AAV vector research, design and evolution. Hum. Gene Ther., 28:1075-86.
  • S. Grosse, M. Penauld-Budloo, A.-K. Herrmann, K. Börner, J. Fakhiri, V. Laketa, C. Krämer, E. Wiedtke, M. Gunkel, L. Menard, E. Ayuso, and D. Grimm. Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells. J. Virol., in press.
  • J. Weinmann, and D. Grimm. Next-generation AAV vectors for clinical use: An ever accelerating race. Virus Genes, 53:707-13.
  • K. Pervorlakari, M.L. Stanifer, S. Münchau, L.A. Renn, D. Albrecht, S. Kurzhals, E. Senís, D. Grimm, J. Schröder-Braunstein, R.L. Rabin, and S. Boulant. Type I and type III interferons display different dependency on MPAKs to mount an antiviral state in the human gut. Frontiers Immunol., 8:459.
  • F.A. Lempp, E. Wiedtke, B. Qu, P. Roques, I. Chemin, F.W.R. Voudran, R.L. Grand, D. Grimm, and S. Urban. Sodium taurocholate cotransporting polypeptide is the limiting host factor of Hepatitis B Virus infection in macaque and pig hepatocytes. Hepatology, 66:703-16.
  • C.S. e Cunha, B. Nyboer, K. Heiss, M. Sanchez-Vaz, D. Fontinha, E. Wiedtke, D. Grimm, J.M. Przyborski, M.M. Mota, M. Prudencio, and A.-K. Mueller. P. berghei EXP-1 interacts with host apolipoprotein H during Plasmodium liver stage development. PNAS, 114:E1138-47.
  • E. Senís, S. Mockenhaupt, D. Rupp, T. Bauer, N. Paramasivam, B. Knapp, J. Gronych, S. Grosse, M.P. Windisch, F. Schmidt, F.J. Theis, R. Eils, P. Lichter, M. Schlesner, R. Bartenschlager, and D. Grimm. TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. Nucleic Acids Res., 45:e3.

2016

  • T. Michler, S. Grosse, S. Mockenhaupt, N. Röder, F. Stückler, B. Knapp, C. Ko, M. Heikenwälder, U. Protzer, and D. Grimm. Blocking sense strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol. Med., 8:1082-98.
  • D. Ebrahimi-Fakhari, L. Wahlster, F. Bartz, J. Werenbeck-Ueding, M. Praggastis, J. Zhang, B. Joggerst-Thomalla, S. Theiss, D. Grimm, D. Ory, and H. Runz. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-Pick type C1 disease cells. Hum. Mol. Gen., 25:3588-99.
  • F.M. Pujol, V. Laketa, F. Schmidt, M. Mukenhirn, B. Müller, S. Boulant, D. Grimm, O.T. Keppler, and O.T. Fackler. HIV-1 Vpu antagonizes CD317/tetherin by adaptor protein-1-mediated exclusion from the virus assembly sites. J. Virol., 90:6709-23.
  • M. Rezvani, R. Espanol-Suner, Y. Malato, L. Dumont, A.A. Grimm, E. Kienle, J.G. Bindman, E. Wiedtke, B.Y. Hsu, S.J. Naqvi, R.F. Schwabe, C.U. Corvera, D. Grimm, and H. Willenbring. In vivo reprogramming of myofibroblasts into hepatocytes as a therapeutic strategy for liver fibrosis. Cell Stem Cell, 18:809-16.
  • F. Hentzschel*, A.-K. Herrmann*, A.-K. Mueller, and D. Grimm. Plasmodium meets AAV - the (un)likely marriage of parasitology and virology, and how to make the match. FEBS Letters, 590:2027-45. (*equal first)
  • C. Liesche, L. Venkatraman, S. Aschenbrenner, S. Grosse, D. Grimm, R. Eils, and J. Beaudouin. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol., 16:17.

2015

  • M. Singer, J. Marshall, K. Heiss, G. Mair, D. Grimm, A.-K. Mueller, and F. Frischknecht. Zinc finger nuclease-induced double-strand breaks lead to attenuated malaria parasites lacking hundreds of genes and reveals rare microhomology-mediated end joining. Genome Biol., 16:249.
  • D. Grimm, and S. Zolotukhin. E pluribus unum: Fifty years of research, millions of viruses, and one goal - tailored acceleration of AAV evolution. Mol. Ther., 23:1819-31.
  • S. Mockenhaupt, S. Grosse, D. Rupp, R. Bartenschlager, and D. Grimm. Alleviation of off-target effects from vector-encoded shRNA via co-delivered RNA decoys. PNAS, 112:E4007-16.
  • S. Mueller, J. Huard, K. Waldow, X. Huang, L.A. D'Alessandro, S. Bohl, K. Börner, D. Grimm, S. Klamt, U. Klingmüller, and M. Schilling. T160-phosphorylated CDK2 defines threshold for HGF-dependent proliferation in primary hepatocytes. Mol. Sys. Biol., 11:795.
  • F. Schmidt, and D. GrimmCRISPR genome engineering and viral gene delivery: A case of mutual attraction. Biotechnol. J., 10:258-72.

2014

  • S. Uhrig-Schmidt, M. Geiger, G. Luippold, G. Birk, D. Mennerich, H. Neubauer, D. Grimm, C. Wolfrum, and S. Kreuz. Gene delivery to adipose tissue using transcriptionally targeted rAAV8 vectors. PLoS ONE, 9:e116288.
  • E. Carnero, M. Barriocanal, V. Segura, E. Guruceaga, C. Prior, K. Börner, D. Grimm, and P. Fortes. Type I interferon regulates the expression of long noncoding RNAs. Frontiers Immunol., 5:548.
  • F. Hentzschel*, C. Hammerschmidt-Kamper*, K. Börner*, K. Heiss*, B. Knapp, J. M. Sattler, L. Kaderali, M. Castoldi, J. G. Bindman, Y. Malato, H. Willenbring, A.-K. Mueller, and D. Grimm. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically-attenuated malarial parasites. Mol. Ther., 22:2130-41. (* equal first)
  • E. Senís*, C. Fatouros*, S. Grosse*, E. Wiedtke, D. Niopek, A.-K. Mueller, K. Börner, and D. Grimm. An adeno-associated viral (AAV) vector toolbox for CRISPR/Cas9-mediated genome engineering. Biotechnol J., 9:1402-12. (* equal first)
  • M. Hörner, B. Kaufmann, G. Cotugno, E. Wiedtke, H. Büning, D. Grimm, and W. Weber. A chemical switch for controlling viral infectivity. Chem. Comm., 50:10319-22.
  • E. Senís, and D. Grimm. From Mice to Men: Towards the Clinical Translation of MicroRNA Technologies for Somatic Cell Reprogramming. In: Applied RNAi: From Fundamental Research To Therapeutic Applications (Caister Academic Press; Eds. P. Arbuthnot & M. Weinberg). p 51-77.

2013

  • N. Schürmann, L. G. Trabuco, C. Bender, R. B. Russell, and D. Grimm. Molecular dissection of human Argonaute proteins using DNA family shuffling. Nat. Struct. & Mol. Biol. 20:818-26.
  • K. Börner, D. Niopek, G. Cotugno, M. Kaldenbach, T. Pankert, J. Willemsen, X. Zhang, N. Schürmann, S. Mockenhaupt, A. Serva, M.S. Hiet, E. Wiedtke, M. Castoldi, V. Starkuviene, H. Erfle, D.F. Gilbert, R. Bartenschlager, M. Boutros, M. Binder, K. Streetz, H.-G. Kräusslich, and D. GrimmRobust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res. 41:e199.
  • S. Heymans, M.F. Corsten, W. Verhesen, P. Carai, R.E. van Leeuwen, K. Custers, T. Peters, M. Hazebroek, L. Stöger, E. Wijnands, B.J. Janssen, E.E. Creemers, Y.M. Pinto, D. Grimm, N. Schürmann, E. Vigorito, T. Thum, F. Stassen, X. Yin, M. Mayr, L.J. de Windt, E. Lutgens, K. Wouters, M.P. de Winther, S. Zacchigna, M. Giacca, M. van Bilsen, A.P. Papageorgiou, and B. Schroen. Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:1420-32.

2012

  • D. Grimm. All for one, one for all: New combinatorial RNAi therapies to defeat Hepatitis C virus evolution. Mol. Ther. 20:1661-3.
  • E. Kienle, E. Senís, K. Börner, D. Niopek, S. Grosse, E. Wiedtke, and D. Grimm. Engineering and evolution of synthetic Adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. J. Vis. Exp. 2: 3819.
  • D. Grimm, T. Dalmay, and R.P. van Rij. Everybody wins! Poland hosts thrilling competitions of viruses, RNAi and football teams. EMBO Rep. 13:874-6.

2011

  • P. Valdmanis, S. Gu, N. Schürmann, P. Sethupathy, D. Grimm, and M.A. Kay. Expression determinants of mammalian Argonaute proteins in mediated gene silencing. Nucleic Acids Res. 40: 3704-13.
  • D. Grimm. The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence 2:8.
  • S. Mockenhaupt, K. Börner, and D. Grimm. Perturbation of the cellular RNAi machinery in disease and therapy: Lessons learned and avenues paved. DGZ Cell News 2:8-16.
  • D. Niopek, R. Berrens, S. Mockenhaupt, M.D. Lewis, A.K. Mueller, and D. Grimm. To go, or not to go, that is the question - six personal reflections on how geographic mobility may affect your career and life. Bioessays 33:728-31.
  • S. Mockenhaupt, and D. Grimm. Adeno-assoziierte Viren für effizientes Gene Targeting in humanen Zellen. BIOspektrum 05/11:533-6.
  • Y. Malato, S. Nagvi, N. Schürmann, R. Ng, B. Wang, J. Zape, M. Kay, D. Grimm, and H. Willenbring. Fate-tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121:4850-60.
  • S. Mockenhaupt, N. Schürmann, and D. Grimm. When cellular networks run out of control: Global dysregulations of the RNAi machinery in human pathology and therapy. Prog. Mol. Biol. Transl. Sci. 2011 102:165-242.
  • S. Gu, L. Jin, F. Zhang, Y. Huang, D. Grimm, J. Rossi, and M.A. Kay. The thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. PNAS 108:9208-13.

2010

  • D. Grimm, L. Wang, J.S. Lee, N. Schürmann, S. Gu, K. Börner, T.A. Storm, and M.A. Kay. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 120:3106-19.
  • S. Beer, D.I. Bellovin, J.S. Lee, K. Komatsubara, L.S. Wang, S. Koh, K. Börner, T.A. Storm, C.R. Davis, M.A. Kay, D.W. Felsher, and D. Grimm. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in mice. Mol. Ther. 18:161-70.
  • K. Börner, and D. Grimm. Use of small RNAs for therapeutic gene silencing: risk versus benefit. Drug Disc. Today: Technol. 7:e51-e57.
  • P. Parameswaran, E. Sklan, T. Burgon, M.A. Samuel, C. Wilkins, R. Lu, K.M. Ansel, V. Heissmeyer, S. Einav, W. Jackson, T. Doukas, S. Paranjape, C. Polacek, F.B. dos Santos, R. Jalili, F. Babrzadeh, B. Gharizadeh, D. Grimm, M. Kay, P. Sarnow, M. Ronaghi, S.-W. Ding, E. Harris, M. Chow, M.S. Diamond, K. Kirkegaard, J. Glenn, and A. Fire. 6 RNA Viruses & 41 hosts: vsRNAs and viral modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathogens, 12: e1000764.
  • D. Grimm. Small Silencing RNAs and Gene Therapy. In: Encylopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester www.els.net [DOI: 10.1002/9780470015902.a0022396]

2009

  • D. Grimm. Small silencing RNAs: State-of-the-art. Adv. Drug Del. Rev. 61:672-703.
  • D. Grimm. Asymmetry in siRNA design. Gene Ther. 16:827-29.
  • D. Grimm. Klein aber ungemein fein: Winzige rekombinante Viren als Träger für RNAi-Moleküle. Bioforum 5:21-23 & 6:12-14.

2008

  • J. Giering, D. Grimm, T.A. Storm, and M.A. Kay. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther.16:1630-6 .
  • D. Grimm, J.S. Lee, L. Wang, T. Desai, B. Akache, T.A. Storm, and M.A. Kay. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and re-targeting of adeno-associated viruses. J. Virol. 82:5887-911. (Faculty of 1000 score of 9.0)
  • H. Doege, D. Grimm, A. Falcon, B. Tsang, T.A. Storm, H. Xu, A.M. Ortegon, M. Kazantzis, M.A. Kay, and A. Stahl. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem. 283:22186-92.
  • K. Streetz, R. Doyonnas, D. Grimm, D.D. Jenkins, S. Fuess, S. Perryman, J. Lin, C. Trautwein, J. Shizuru, H. Blau, K.G. Sylvester, and M.A. Kay. Successful engraftment of transplanted allogeneic hepatocytes is mediated by bone marrow transplantation and in vivo CD4(+) cell selection. Hepatology, 47:706-18.

2007

  • D. Grimm, and M.A. Kay. Therapeutic RNAi applications: Is mRNA targeting finally ready for prime-time ? J. Clin. Invest. 117:3633-41.
  • D.M. Paskowitz, K.P. Greenberg, D. Yasumura, D. Grimm, J.L. Duncan, M.A. Kay, M.M. LaVail, J.G. Flannery, and D. Vollrath. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Hum. Gene Ther. 18: 871-80.
  • B. Akache, D. Grimm, X. Shen, S. Fuess, S.R. Yant, D.S. Glazer, J. Park, and M.A. Kay. A two-hybrid screen identifies cathepsins B and L as potential uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-9.
  • D. Grimm, and M.A. Kay. RNAi and gene therapy: A mutual attraction. Hematology Am. Soc. Hematol. Educ. Program 2007, 2007:473-81.
  • D. Grimm, and M.A. Kay.Combinatorial RNAi: A winning strategy for the race against evolving targets ? Mol. Ther., 15:878-88.

2006

  • D. Grimm, K.S. Streetz, C.L. Jopling, T.A. Storm, K. Pandey, C.R. Davis, P. Marion, F. Salazar, and M.A. Kay. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-41. (Faculty of 1000 score of 6.4)
  • D. Grimm, and M.A. Kay. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. 13:563-75.
  • D. Grimm, K. Pandey, H. Nakai, T.A. Storm, and M.A. Kay. Liver transduction with recombinant Adeno-associated virus is primarily restricted by viral serotype, not vector genotype. J. Virol. 80:429-36.
  • B. Akache, D. Grimm, K. Pandey, S. Yant, H. Xu, and M.A. Kay. The 37/67-kildodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-6.
  • O.J. Müller, B. Leuchs, S.T. Pleger, D. Grimm, W.M. Franz, H.A. Katus, and J.A. Kleinschmidt. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res.70:70-8 .

2005

  • E. Riu, D. Grimm, Z. Huang, and M.A. Kay. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum. Gene Ther. 16:558-70.
  • D. Grimm, K. Pandey, and M.A. Kay. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. 392:381-405.

2004

  • D. Grimm, and M.A. Kay. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3:281-304.

2003

  • D. Grimm, S. Zhou, H. Nakai, C.E. Thomas, T.A. Storm, S. Fuess, T. Matsushita, J. Allen, R. Surosky, M. Lochrie, L. Meuse, A. McClelland, P. Colosi, and M.A. Kay. Pre-clinical in vivo evaluation of pseudotyped adeno-associated virus (AAV) vectors for liver gene therapy. Blood 102:2412-9.
  • D. Grimm, M.A. Kay, and J.A. Kleinschmidt. Helper virus-free, optically-controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7:839-50.

2002

  • D. Grimm. (Update 2008). AAV. In: Encyclopedic Reference of Cancer. Springer Verlag, Heidelberg. (Ed. M. Schwab). 5-10.
  • N. Salome, and D. Grimm. Gentherapie mit Parvoviren ? In: Krebsforschung heute. Berichte aus dem Deutschen Krebsforschungszentrum. Steinkopff Darmstadt. (Ed. H. Stamatiadis-Smidt). 168-73.
  • D. Grimm. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 28:146-57.
  • U.P. Rohr, R. Kronenwett, D. Grimm, J. Kleinschmidt, and R. Haas. Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J. Virol. Meth. 105:265-75.

2001

  • J.A. King, R. Dubielzig, D. Grimm, and J.A. Kleinschmidt. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 20:3282-91.
  • S. Jiang, A. Altmann, D. Grimm, J.A. Kleinschmidt, T. Schilling, C. Germann, and U. Haberkorn. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. 8:469-72.
  • J. Smith, R. Herrero, K. Erles, D. Grimm, N. Munoz, F.X. Bosch, L. Tafur, K.V. Shah, and J.R. Schlehofer. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. Int. J. Cancer  94:520-6.

2000

  • D. Kunke, D. Grimm, S. Denger, J. Kreuzer, H. Delius, D. Komitowski, and J.A. Kleinschmidt. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther. 7:766-77.
  • D. Grimm. Adeno-associated virus (AAV) serotypes as vectors for human gene therapy. In: Research advances in virology. Global Research Network, India. (Ed. R. M. Mohan). 91-114.
  • D. Grimm, and J.A. Kleinschmidt. Strategies for production of adeno-associated virus vectors. In: Viral Vectors: Basic Science & Gene Therapy. Eaton Publishing, Natick, MA. (Eds. A. Cid-Arregui and A. Garcia). 27-57.

1999

  • D. Grimm, and J.A. Kleinschmidt. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum. Gene Ther.10:2445-50 .
  • D. Grimm, A. Kern, M. Pawlita, F. Ferrari, R. Samulski, and J.A. Kleinschmidt. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6:1322-30.
  • A. Hörster, B. Teichmann, R. Hormes, D. Grimm, J. Kleinschmidt, and G. Sczakiel. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy. Gene Ther. 6:1231-8.
  • W.T. Hermens, O. ter Brake, P.A. Dijkhuizen, M.A. Sonnemans, D. Grimm, J.A. Kleinschmidt, and J. Verhaagen. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. 10:1885-91.

1998

  • D. Grimm, A. Kern, K. Rittner, and J.A. Kleinschmidt. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther.9:2745-60 .

1997

  • A. Wistuba, A. Kern, S. Weger, D. Grimm, and J.A. Kleinschmidt. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol.71:1341-52 .
  • S. Weger, A. Wistuba, D. Grimm, and J.A. Kleinschmidt. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. J. Virol. 71:8437-47.

To top

Contact: E-Mail (Last update: 21/10/2017)